Résumé
OBJECTIVES@#To investigate the difference in the therapeutic effect of mycophenolate mofetil (MMF) or cyclophosphamide (CTX) in children with Henoch-Schönlein purpura nephritis (HSPN) of different age groups.@*METHODS@#A retrospective analysis was conducted on the clinical data of 135 children with HSPN who were treated with MMF or CTX in the Department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics, from October 2018 to October 2020. According to the immunosuppressant used, they were divided into two groups: MMF group and CTX group, and according to the age, each group was further divided into two subgroups: ≤12 years and >12 years, producing four groups, i.e, the ≤12 years MMF subgroup (n=30), the >12 years MMF subgroup (n=15), the ≤12 years CTX subgroup (n=71), and the >12 years CTX subgroup (n=19). All children were followed up for at least 12 months, and the above groups were compared in terms of clinical outcomes and the incidence rate of adverse reactions.@*RESULTS@#There was no significant difference in the complete response rate between the MMF group and the CTX group after 3, 6, and 12 months of treatment (P>0.05). There were no significant difference in the complete response rate and the incidence rate of adverse reactions between the >12 years MMF subgroup and the ≤12 years MMF subgroup at 3, 6, and 12 months of treatment (P>0.05). The >12 years CTX subgroup had a significantly lower complete response rate than the ≤12 years CTX subgroup at 6 and 12 months of treatment (P<0.05). The >12 years CTX subgroup had a significantly higher incidence rate of adverse reactions than the >12 years MMF subgroup (P<0.05).@*CONCLUSIONS@#The efficacy and adverse reactions of MMF are not associated with age, but the efficacy of CTX is affected by age, with a higher incidence rate of adverse reactions. CTX should be selected with caution for children with HSPN aged >12 years.
Sujets)
Enfant , Humains , Acide mycophénolique/effets indésirables , /traitement médicamenteux , Études rétrospectives , Cyclophosphamide/effets indésirables , Immunosuppresseurs/effets indésirables , Vascularite/traitement médicamenteux , Néphrite/complicationsRésumé
Kawasaki disease (KD) is an acute self-limiting vasculitis, and it is the most common cause of acquired heart disease in children under 5 years old. One of the improvement goals in pediatric quality control work for the year 2023, as announced by the National Health Commission, is to reduce the incidence of cardiac events and KD-related mortality in children with KD. In order to standardize the diagnosis, treatment, and long-term management practices of KD in China, and effectively prevent and reduce the incidence of coronary artery lesions and long-term adverse effects, the guideline working group followed the principles and methods outlined by the World Health Organization and referenced existing evidence and experiences to develop the "Evidence-based guidelines for the diagnosis and treatment of Kawasaki disease in children in China (2023)". The guidelines address the clinical questions regarding the classification and definition of KD, diagnosis of different types of KD, treatment during the acute phase of KD, application of echocardiography in identifying complications of KD, and management of KD combined with macrophage activation syndrome. Based on the best evidence and expert consensus, 20 recommendations were formulated, aiming to provide guidance and decision-making basis for healthcare professionals in the diagnosis and treatment of KD in children.
Sujets)
Enfant , Humains , Enfant d'âge préscolaire , Maladie de Kawasaki/complications , Vascularite/traitement médicamenteux , Coeur , Cardiopathies , Chine , Immunoglobulines par voie veineuse/usage thérapeutiqueRésumé
Abstract Methotrexate is an effective medication to control several diseases; however, it can be very toxic, being myelosuppression one of its main adverse effects, which increases in severity and frequency in patients with renal failure. We present the case of a 68-year-old man with chronic, end-stage renal disease associated with ANCA vasculitis, under treatment with peritoneal dialysis, who received the medication at a low dose, indicated by disease activity, which presented as a complication with severe pancytopenia with mucositis that improved with support measures and multiple-exchange peritoneal dialysis. We reviewed 20 cases published to date of pancytopenia associated with methotrexate in patients on dialysis and found high morbidity and mortality, which is why its use in this type of patient is not recommended. However, when this complication occurs, a therapeutic option could be the use of multiple-exchange peritoneal dialysis in addition to supportive therapy for drug-related toxicity, although it is recognized that studies are required to show the role of multiple-exchange peritoneal dialysis in the removal of this medication.
Resumo Apesar de sua toxicidade, o metotrexato é um medicamento eficaz no controle de várias doenças. A mielossupressão, um de seus principais efeitos adversos, aumenta em gravidade e frequência nos pacientes com insuficiência renal. Apresentamos o caso de um homem de 68 anos de idade com doença renal terminal relacionada à vasculite associada ao ANCA em diálise peritoneal, que recebeu a medicação em dose baixa em função da atividade da doença e que teve como complicação pancitopenia grave com mucosite, tratada com medidas de suporte e diálise peritoneal com múltiplas trocas. Revisamos 20 casos publicados até o presente momento sobre pancitopenia associada a metotrexato em pacientes em diálise. Foi identificada alta morbidade e mortalidade, razão pela qual seu uso nesse tipo de paciente não é recomendado. No entanto, quando esta complicação ocorre, uma opção terapêutica pode ser o uso de diálise peritoneal com múltiplas trocas, além da terapia de suporte para toxicidade medicamentosa. Maiores estudos são necessários para demonstrar o papel da diálise peritoneal com múltiplas trocas na remoção desse medicamento.
Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Sujet âgé , Vascularite/traitement médicamenteux , Méthotrexate/effets indésirables , Méthotrexate/usage thérapeutique , Dialyse péritonéale/méthodes , Antifoliques/effets indésirables , Antifoliques/usage thérapeutique , Défaillance rénale chronique/thérapie , Pancytopénie/étiologie , Pancytopénie/thérapie , Choc septique/étiologie , Choc septique/traitement médicamenteux , Méthotrexate/sang , Résultat thérapeutique , Inflammation muqueuse/étiologie , Inflammation muqueuse/traitement médicamenteux , Antifoliques/sang , Antibactériens/usage thérapeutiqueRésumé
Abstract: Background: Varicose veins and the complications of venous disease are common disorders in humans. Objective: To study the effects of bleomycin as a potential new sclerosing agent and its adverse events in treating varicose veins. Methods: Bleomycin-loaded liposomes 0.1ml was injected in the dorsal ear veins of white New Zealand rabbits. Sodium tetradecyl sulfate was used as a positive control. Normal saline was used as negative control. The blood vessels of the treated ears were photographed before and at one hour and two, eight and 45 days after treatment. Biopsies from the treated areas were obtained for histological examination. Blood samples were collected to determine any possible toxicity. Results: Bleomycin by itself was ineffective; therefore, liposomes were used as a vector to deliver bleomycin to the vein lumen. Subsequently, bleomycin started showing its sclerosing effects. Toxicity monitoring showed no apparent hematologic, pulmonary, hepatic or renal toxicities. This study revealed that bleomycin induced vasculitis, which led to vascular occlusion, which was observed on day 1 and day 8. No bleomycin-related injury was noted by histopathological examination of lung sections. The calculation of the lung/body weight coefficient indicated that edema was present in the experimental groups compared with the negative and positive controls. Study limitations: Relatively small number of experimental animals used. Conclusions: This study showed that bleomycin-loaded liposomes were able to induce vasculitis and vascular occlusion without any toxicity or complications. It might be useful, hence, to treat patients suffering from Varicose veins and other ectatic vascular diseases with this agent.
Sujets)
Animaux , Lapins , Solutions sclérosantes/pharmacologie , Tétradécyl-sulfate de sodium/administration et posologie , Varices/thérapie , Bléomycine/pharmacologie , Sclérothérapie/méthodes , Antibiotiques antinéoplasiques/administration et posologie , Solutions sclérosantes/administration et posologie , Solutions sclérosantes/effets indésirables , Vascularite/induit chimiquement , Vascularite/traitement médicamenteux , Veines/effets des médicaments et des substances chimiques , Bléomycine/administration et posologie , Modèles animaux de maladie humaine , Évaluation préclinique de médicament , Injections veineuses , LiposomesRésumé
INTRODUCCIÓN: Las vasculitis son un conjunto heterogéneo de enfermedades sistémicas caracterizadas por la inflamación y en cierta medida destrucción de los vasos sanguíneos, por ende, afectan la perfusión o permeabilidad de dichos vasos (1,2). La vasculitis asociada a ANCA se caracteriza por ser una vasculitis necrotizante de pequeños vasos (arteriola, capilar y vénula) con afectación ocasional de arterias y venas viscerales, sin depósitos inmunes en las lesiones y asociadas a la presencia de autoanticuerpos contra el citoplasma de los neutrófilos, cuyos antígenos son la mieloperoxidasa (MPO) y la proteinasa 3 (PR3). TECNOLOGÍA SANITARIA ANALIZADA: Rituximab. EFICACIA DE LOS TRATAMENTOS: Entre las conclusiones que se pueden extraer acerca de la efectividad del Rituximab para el tratamiento de las Vasculitis asociadas a ANCA se encuentran: - Rituximab podría aumentar levemente la tasa de inducción de remisión. La certeza de la evidencia es baja. - Existe incertidumbre sobre si Rituximab podría aumentar o disminuir la mortalidad general. La certeza de la evidencia es muy baja. - Rituximab podría aumentar la incidencia de infecciones. La certeza de la evidencia es baja. - Existe incertidumbre sobre si Rituximab podría favorecer o no el desarrollo de neoplasias. La certeza de la evidencia es muy baja. EVALUACIÓN ECONÓMICA: No se evaluó esta dimensión, en conformidad con el Título III De las Evaluaciones Favorables de la Norma Técnica N° 0192 del Ministerio de Salud, sobre el proceso de evaluación científica de la Evidencia establecido en el artículo 7° de la ley N°20.850. CONCLUSIÓN: Para dar cumplimiento al artículo 28° del Reglamento que establece el proceso destinado a determinar los diagnósticos y tratamientos de alto costo con Sistema de Protección Financiera, según lo establecido en los artículos 7°y 8° de la ley N°20.850, aprobado por el decreto N°13 del Ministerio de Salud, se concluye que el presente informe de evaluación se considera no favorable, dado que la evidencia presentada es de certeza muy baja, de acuerdo a lo establecido en el Título III. de las Evaluaciones Favorables de la Norma Técnica N° 0192 de este mismo Ministerio.
Sujets)
Humains , Vascularite/traitement médicamenteux , Rituximab/usage thérapeutique , Évaluation de la technologie biomédicale/économie , Évaluation de la Santé/économieRésumé
Resumo O maior entendimento das bases fisiopatológicas e do comportamento das vasculites sistêmicas, aliado ao desenvolvimento de regimes terapêuticos com perfil de segurança e eficácia cada vezes melhores, modificou drasticamente o prognóstico dos pacientes diagnosticados com essas entidades clínicas. Recentemente, o emprego do rituximabe no tratamento de pacientes com vasculites ANCA associadas em ensaios clínicos randomizados se mostrou uma opção importante em casos selecionados, especialmente pacientes refratários ou intolerantes à terapia-padrão com ciclofosfamida e corticosteroides. O presente artigo traz o relato de sete casos de vasculites sistêmicas com tratamento bem-sucedido com rituximabe.
Abstract The greater understanding of pathophysiology and behavior of systemic vasculitis, together with the development of therapeutic regimens with increasingly better safety and efficacy profiles, dramatically changed the prognosis of patients diagnosed with these clinical entities. Recently, the use of rituximab in the treatment of patients with ANCA-associated vasculitis in randomized clinical trials showed an important alternative in selected cases, especially patients refractory or intolerant to standard therapy with cyclophosphamide and corticosteroids. This article presents the report of seven cases of systemic vasculitis successfully treated with rituximab.
Sujets)
Humains , Mâle , Femelle , Adulte , Jeune adulte , Vascularite/traitement médicamenteux , Antirhumatismaux/usage thérapeutique , Rituximab/usage thérapeutique , Essais contrôlés randomisés comme sujet , Hormones corticosurrénaliennes/usage thérapeutique , Cyclophosphamide/usage thérapeutique , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/traitement médicamenteux , Anticorps monoclonaux d'origine murine/effets indésirables , Adulte d'âge moyenRésumé
Se presenta el caso clínico de un paciente de 54 años, negativo para VIH, con enfermedad cerebrovascular por trombosis de la arteria basilar, secundaria a neurosífilis meningovascular. La neurosífilis es el compromiso del sistema nervioso central por Treponema pallidum subespecie pallidum en cualquier estadio de la entidad e incluye las formas asintomáticas y sintomáticas de la infección; sus formas de presentación son diversas y dependen de la localización y la extensión de las lesiones. La recomendación actual es el tratamiento con 4 millones de unidades de penicilina cristalina cada 4 horas por 14 días.
Herein a case is described of a 54-years old patient, HIV negative, with cerebro-vascular disease by basilar artery thrombosis secondary to meningovascular neurosyphilis. Neurosyphilis is the impairment at any stage of the central nervous system by Treponema pallidum subspecies pallidum and includes asymptomatic and symptomatic forms of infection. The presentation can take many forms, depending on the location and extent of tissue damage. The currently recommended treatment is crystalline penicillin, 4 million units every 4 hours for 14 days.
Sujets)
Humains , Mâle , Adulte d'âge moyen , Méningite/étiologie , Neurosyphilis/complications , Thrombose/étiologie , Vascularite/étiologie , Insuffisance vertébrobasilaire/étiologie , Alcoolisme/complications , Antibactériens/usage thérapeutique , Association thérapeutique , Dysarthrie/étiologie , Urgences , Procédures endovasculaires , Séronégativité VIH , Hypertension artérielle/complications , Imagerie par résonance magnétique , Méningite/traitement médicamenteux , Neurosyphilis/traitement médicamenteux , Parésie/étiologie , Benzylpénicilline/usage thérapeutique , Endoprothèses , Thrombectomie , Tomodensitométrie , Thrombose/traitement médicamenteux , Thrombose , Thrombose/chirurgie , Vascularite/traitement médicamenteux , Insuffisance vertébrobasilaire/diagnostic , Insuffisance vertébrobasilaire , Insuffisance vertébrobasilaire/chirurgieRésumé
Recurrent cutaneous necrotizing eosinophilic vasculitis (RCNEV) is a rare disease characterized by clinical features of pruritic purpuric papules and angioedema. Skin biopsies revealed the eosinophil-predominate necrotizing vasculitis affecting small dermal vessels. Systemic corticosteroid is a very effective treatment. There are many side effects associated with systemic corticosteroid therapy. The authors report a case of RCNEVsuccessfully treated with indomethacin. To the authors'knowledge, there has been no reported case of RCNEV treated with indomethacin.
Sujets)
Anti-inflammatoires non stéroïdiens/usage thérapeutique , Éosinophilie/traitement médicamenteux , Granulocytes éosinophiles , Humains , Indométacine/usage thérapeutique , Mâle , Adulte d'âge moyen , Nécrose/traitement médicamenteux , Récidive , Dermatoses vasculaires/traitement médicamenteux , Vascularite/traitement médicamenteuxRésumé
La paquimeningitis hipertrófica es una enfermedad poco frecuente caracterizada por engrosamiento de la duramadre. Presentamos una paciente con esta enfermedad que se manifestó con cefalea crónica y en la que concomitantemente se evidenció una glomerulonefritis necrotizante extracapilar pauciinmune asociada a anticuerpos anticitoplasma de neutrófilos de patrón perinuclear (ANCA-P). El diagnóstico se estableció por resonancia nuclear magnética. Recibió tratamiento inmunosupresor con prednisona y ciclofosfamida con evolución favorable.
Hypertrophic pachymeningitis is a very unusual disease, the main characteristic of which is thickening of the dura mater. We describe a patient who started this illness showing chronic headache and pauci-immune necrotizing extracapillary perinuclear antineutrophil cytoplasmic antibody (P-ANCA) associated glomerulonephritis. The diagnosis was made by brain magnetic resonance image. She received immunosuppressant therapy with prednisonel and cyclophosphamide with clinical improvement.
Sujets)
Humains , Femelle , Adulte , Anticorps anti-cytoplasme des polynucléaires neutrophiles/sang , Glomérulonéphrite/étiologie , Méningite/étiologie , Vascularite/complications , Anti-inflammatoires/usage thérapeutique , Cyclophosphamide , Glomérulonéphrite/diagnostic , Glomérulonéphrite/traitement médicamenteux , Céphalée/étiologie , Immunosuppresseurs/usage thérapeutique , Imagerie par résonance magnétique , Méningite/diagnostic , Méningite/traitement médicamenteux , Prednisolone/usage thérapeutique , Vascularite/traitement médicamenteux , Vascularite/immunologieRésumé
OBJECTIVE: To describe the clinical spectrum, laboratory features, histopathological findings and treatment outcome in patients with classical polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA). MATERIAL AND METHODS: Patients with PAN and MPA seen at a large teaching hospital in north India over a period of five years (1994-99) were included in the present study. RESULTS: We encountered five patients with PAN and six patients with MPA during the study period. Of the five patients with PAN, two had systemic disease while three had limited PAN. The patients with limited PAN included two with cutaneous PAN and one with PAN confined to the nerves. Constitutional symptoms, musculoskeletal complaints, peripheral neuropathy and skin lesions dominated the clinical picture. Fifty percent of the MPA patients presented as pulmonary renal syndrome. All the patients with PAN were HBsAg and ANCA negative and had normal urinalysis findings. In contrast, all patients with MPA demonstrated an active urine sediment and 83.3% were pANCA positive. Some of the rare features encountered by us were the presence of antiphospholipid syndrome and extensive interstitial lung disease in MPA, and spontaneous recovery in one patient with systemic PAN. Treatment outcome was better in PAN as compared with MPA. CONCLUSIONS: The clinical spectrum of PAN and MPA is quite varied. A good outcome is possible with the use of corticosteroids and cyclophosphamide.
Sujets)
Adolescent , Adulte , Sujet âgé , Anti-inflammatoires/usage thérapeutique , Anticorps anti-cytoplasme des polynucléaires neutrophiles/sang , Enfant , Enfant d'âge préscolaire , Cyclophosphamide/usage thérapeutique , Femelle , Humains , Nourrisson , Rein/anatomopathologie , Poumon/anatomopathologie , Mâle , Adulte d'âge moyen , Polyartérite noueuse/traitement médicamenteux , Prednisolone/usage thérapeutique , Pronostic , Études prospectives , Études rétrospectives , Tomodensitométrie , Vascularite/traitement médicamenteuxSujets)
Administration par voie orale , Adulte , Lymphocytes B/effets des médicaments et des substances chimiques , Division cellulaire/effets des médicaments et des substances chimiques , Humains , Immunosuppresseurs/administration et posologie , Activation des lymphocytes/effets des médicaments et des substances chimiques , Méthotrexate/administration et posologie , Rétine/effets des médicaments et des substances chimiques , Rétinopathies/traitement médicamenteux , Études rétrospectives , Sécurité , Lymphocytes T/effets des médicaments et des substances chimiques , Vascularite/traitement médicamenteuxRésumé
We report a 46-year-old woman with primary biliary cirrhosis (PBC) presenting with Sjogren's syndrome and systemic mononuclear inflammatory vasculopathy. Biopsy specimens of sural nerve showed findings consistent with vasculitic neuropathy. Perivascular inflammatory mononuclear cell infiltration was observed on muscle biopsy specimen. The findings of abdominal computed tomography and brain magnetic resonance imaging were suggestive of vasculitis. Clinical manifestations and radiologic findings were improved after high dose prednisolone therapy.
Sujets)
Femelle , Humains , Ponction-biopsie à l'aiguille , Diagnostic différentiel , Études de suivi , Cirrhose biliaire , Cirrhose biliaire , Adulte d'âge moyen , Prednisone , Syndrome de Gougerot-Sjögren/anatomopathologie , Syndrome de Gougerot-Sjögren , Syndrome de Gougerot-Sjögren/complications , Nerf sural/anatomopathologie , Résultat thérapeutique , Vascularite/anatomopathologie , Vascularite/traitement médicamenteux , Vascularite , Vascularite/complicationsRésumé
Informamos el caso de una mujer con síndrome de Cogan manifestado por queratitis intersticial, daño vestíbulo-coclear y polineuropatía craneal. El tratamiento inicial consistió en dosis altas de esteroides, agentes alquilantes y metotrexate sin mejoría. Hubo una excelente respuesta a la ciclosporina (C y A) en dosis de 4-5 mg/Kg y, con este tratamiento, ha mantenido una adecuada evolución por los últimos cinco años. Es de notar que el indicador más sobresaliente de actividad de la enfermedad fue la trombocitosis. Se discuten las modalidades más recientes de tratamiento
Sujets)
Humains , Femelle , Adulte d'âge moyen , Vascularite/traitement médicamenteux , Ciclosporine/usage thérapeutique , Kératite , Maladies de l'appareil lacrymal , Numération des plaquettes/effets des médicaments et des substances chimiquesSujets)
Humains , Polyarthrite rhumatoïde/traitement médicamenteux , Vascularite/traitement médicamenteux , Prednisone/administration et posologie , Prednisone/usage thérapeutique , Posologie Homéopathique , Glucocorticoïdes/administration et posologie , Glucocorticoïdes/usage thérapeutique , Formes posologiques , Lupus érythémateux disséminé/traitement médicamenteux , Relation dose-effet des médicamentsSujets)
Humains , Vascularite/classification , Vascularite/physiopathologie , Vascularite/traitement médicamenteux , Granulomatose avec polyangéite/traitement médicamenteux , Hormones corticosurrénaliennes/administration et posologie , Hormones corticosurrénaliennes/usage thérapeutique , Maladie grave/thérapie , Polyartérite noueuse/traitement médicamenteux , Cryoglobulinémie/traitement médicamenteux , /traitement médicamenteux , Maladie de Behçet/traitement médicamenteux , Maladie de Kawasaki/traitement médicamenteuxRésumé
Objetivo: realizar una revisión de la literatura reciente con respecto a la utilidad de marcadores de actividad de las vasculitis. Fuente de datos: se realizó una búsqueda en la base de datos Medline (1989 a 1996), que comprendía tópicos relacionados con criterios de actividad clínica y de laboratorio de las vasculitis, además de los estudios que se han adelantado con respecto a las moléculas de adhesión, las citoquinas, los ANCAs, los anticuerpos anti-célula endotelial, el factor reumatoideo, la proteína C reactiva y los marcadores de daño endotelial en lo que respecta a su participación patogénica y su posible aplicabilidad clínica. Selección del estudio: se estudiaron 450 resúmenes de los cuales, de los cuales 90 informaban sobre tópicos relacionados con el tema. Extracción de los datos: los artículos se clasificaron de acuerdo con sus objetivos y estrategias de ejecución, según se trataran de revisiones, artículos originales o informes de casos. Recopilamos y analizamos los artículos originales y luego elaboramos la revisión, los resúmenes y las conclusiones. Síntesis de datos: los estudios recientes con respecto a los niveles séricos de moléculas de adhesión, citoquinas y diversos anticuerpos, que permiten entender la patogénesis de la vasculitis, también hacen plantear al clínico y a los investigadores su posible utilidad como elementos clasificatorios de diagnóstico, actividad y daño, en una forma más precisa, con un enfoque creíble, estandarizado, reproducible y de fácil ejecución. Conclusión: los criterios de actividad y daño de las vasculitis, son elementos que facilitan la labor del médico que trata este tipo de pacientes, dado que le permiten definir el tipo y grado de inmunosupresión, la diferenciación de recaídas y de reacciones adversas medicamentosas o infecciones concomitantes. También son útiles al investigador que evalúa las respuestas de medicamentos o los aspectos biológicos y bioquímicos de estas enfermedades
Sujets)
Humains , Vascularite/classification , Vascularite/complications , Vascularite/diagnostic , Vascularite/traitement médicamenteux , Vascularite/épidémiologie , Vascularite/étiologie , Vascularite/physiopathologie , Vascularite/thérapieRésumé
La asociación de vasculitis con enfermedades del tejido conectivo es bien conocida y con frecuencia producen eventos oclusivos vasculares; informamos los casos de un paciente con lupus eritematoso sistémico y otro con artritis reumatoidea, con vasculitis reumatoidea y síndrome antifosfolípido secundario, que desarrollaron oclusión arterial en miembros inferiores y que requirieron amputación en quienes se documentó la presencia de vasculitis, vasculopatía y trombo organizado. La pérdida dramática de tejido es rara para vasculitis aislada o síndrome antifosfolípido primario. Sugerimo en pacientes con estas enfermedades que cursen con compromiso vascular rápidamete progresivo sospechar la asociación de vasculitis y trombosis e iniciar manejo agresivo con inmunosupresores, antiagregantes plaquetarios y vasodilatadores
Sujets)
Humains , Femelle , Adulte , Syndrome des anticorps antiphospholipides/chirurgie , Syndrome des anticorps antiphospholipides/classification , Syndrome des anticorps antiphospholipides/complications , Syndrome des anticorps antiphospholipides/diagnostic , Syndrome des anticorps antiphospholipides/épidémiologie , Syndrome des anticorps antiphospholipides/étiologie , Syndrome des anticorps antiphospholipides/physiopathologie , Syndrome des anticorps antiphospholipides/anatomopathologie , Syndrome des anticorps antiphospholipides/traitement médicamenteux , Syndrome des anticorps antiphospholipides/thérapie , Vascularite/classification , Vascularite/complications , Vascularite/diagnostic , Vascularite/traitement médicamenteux , Vascularite/épidémiologie , Vascularite/étiologie , Vascularite/anatomopathologie , Vascularite/physiopathologie , Vascularite/chirurgie , Vascularite/thérapieRésumé
O comprometimento do sistema nervoso periférico é frequente nas vasculites sistêmicas e contribui decisivamente para o diagnóstico. Oito pacientes foram estudados: sete do sexo feminino e um do sexo masculino; cinco brancos, dois negros, um amarelo; média de idade de 55,9 anos; quatro com poliarterite nodosa, um com lúpus eritematoso sistêmico, um com artrite reumatóide, um com vasculite isolada do sistema nervoso periférico e um com vasculite livedóide. Todos foram submetidos a terapêutica intravenosa com pulsos mensais de metilprednisolona (1 g/dia/3dias) e ciclofosfamida (1 g/dia). Cinco pacientes melhoraram, dois permaneceram inalterados e um faleceu. A melhora neurológica objetiva ocorreu após o terceiro ou quarto pulso e nos pacientes com menor duraçao da doença.